

5. References

- [1] Ministry of Health, Labour and Welfare. Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices (act no. 145 of 1960) (amendment of act no. 63 of 2019). 2019.
- [2] Ministry of Health, Labour and Welfare. Ministerial ordinance partially revising the ministerial ordinance no.116. 2017.
- [3] Cabinet Public Affairs Office, Cabinet Secretariat. Japan revitalization strategy 2016 [in Japanese]. https://www.kantei.go.jp/jp/singi/keizaisaisei/pdf/2016_zentaihombun.pdf.
- [4] Pharmaceuticals and Medical Devices Agency. MID-NET (Medical information database network) [in Japanese]. <https://www.pmda.go.jp/safety/mid-net/0001.html>
- [5] Ministry of Health, Labour and Welfare. Basic principles on the use of medical information databases in post-marketing pharmacovigilance (PSEHB/PED notification no. 0609–8, PSEHB/ DS notification no. 0609–4) [in Japanese]. 2017.
- [6] Ministry of Health, Labour and Welfare. Partially revising the ministerial ordinance no.135 (PFSB notification no.0311-7) [in Japanese]. 2013.
- [7] Ministry of Health, Labour and Welfare. Ministerial ordinance no.135. 2004.
- [8] Ministry of Health, Labour and Welfare. Risk management plan guidance (PFSB/SD notification no. 0411-1, PFSB/ELD notification no. 0411-2).
<https://www.pmda.go.jp/files/000153333.pdf>
- [9] Ministry of Health, Labour and Welfare. Pharmaceutical and medical devices safety information no. 324 July 2015. 2015.
- [10] Pharmaceuticals and Medical Devices Agency. Procedures for developing post-marketing study plan. 2018.
- [11] Post-Marketing Surveillance Subcommittee, Drug Evaluation Committee, Japan

- Pharmaceutical Manufacturers Association. Potential of drug use-results survey data for pharmacoepidemiological research. *Jpn J Pharmacoepidemiol*. 2009.
<https://doi.org/10.3820/jjpe.14.53>
- [12] Ishiguro C, Misu T, Iwasa E, Izawa T. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency. *Pharmacoepidemiology and drug safety*. 2017;26(11):1314-1320. <https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.4252> doi: 10.1002/pds.4252.
- [13] Takahashi N, Otake R, Hokugo J, et al. The survey of trends on Japanese post-marketing study after enforcement of revised good post-marketing study Practice (GPSP). *Japanese journal of pharmacoepidemiology*.2020;25(1):17- 27.
<https://go.exlibris.link/35cWVv84> doi:10.3820/jjpe.25.17.
- [14] Kohama M, Nonaka T, Uyama Y, Ishiguro C. Descriptive analysis for the trend of pharmacovigilance planning in risk management plans on new drugs approved during 2016-2019. *Ther Innov Regul Sci*. 2023;57(1):37-47.
<https://link.springer.com/article/10.1007/s43441-022-00437-6> doi: 10.1007/s43441-022-00437-6.
- [15] EPS Corporation. E-RMP update [in Japanese]. https://www.eps.co.jp/ja/service_ermupdate.php (Access: April 24, 2022)
- [16] Pharmaceuticals and Medical Devices Agency. List of approved products. <https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html>
- [17] Pharmaceuticals and Medical Devices Agency. List of RMPs for new drugs [in Japanese]. <https://www.pmda.go.jp/safety/info-services/drugs/items-information/rmp/0001.html>
- [18] Pharmaceuticals and Medical Devices Agency. Review reports [in

- Japanese]. <https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0020.html>
- [19] Pharmaceuticals and Medical Devices Agency. Search engine for prescription drugs. <https://www.pmda.go.jp/PmdaSearch/iyakuSearch/>.
- [20] Pharmaceuticals and Medical Devices Agency. Review report for Zymso intravesical solution 50%. 2021.
https://www.pmda.go.jp/drugs/2020/P20201223003/230109000_30300AMX00029_A100_1.pdf
- [21] Pharmaceuticals and Medical Devices Agency. Review report for Axumin injection. 2021.
https://www.pmda.go.jp/drugs/2021/P20210330001/530359000_30300AMX00246_A100_1.pdf
- [22] Janssen Pharmaceutical KK. Risk management plan for Imbruvica capsules 140 mg. 2021. https://www.pmda.go.jp/RMP/www/800155/9ff47405-2ac9-4c5c-90ef-0e0b7a01470c/800155_4291043M1027_007RMP.pdf
- [23] Clinical innovation network home. [in Japanese] <https://cinc.ncgm.go.jp/info/about/>
- [24] Ministry of Health, Labour and Welfare. Points to consider for ensuring the reliability of post-marketing database study for drugs (PSEHB/PED notification no. 0221–1). 2018.
<https://www.pmda.go.jp/files/000243761.pdf>
- [25] HIV related drugs. HRD web site. [in Japanese].
<https://www.hrd.gr.jp/common/outline/outline.html>
- [26] Pharmaceuticals and Medical Devices Agency. Guidelines for the conduct of pharmacoepidemiological studies in drug safety assessment with medical information databases. <https://www.pmda.go.jp/files/000240951.pdf>. Updated 2014.
- [27] World Health Organization. ATC/DDD index

2023. https://www.whooc.no/atc_ddd_index/.

[28] MedDRA M. MedDRA hierarchy. <https://www.meddra.org/how-to-use/basics/hierarchy>